Enzyme involved in cancer growth imaged for first time
A study has revealed the structure of an enzyme that promotes cancer growth by mutating RNA, which could be used in the development of cancer treatments.
List view / Grid view
Enzymes are macromolecular biological catalysts. Enzymes accelerate, or catalyse, chemical reactions.
A study has revealed the structure of an enzyme that promotes cancer growth by mutating RNA, which could be used in the development of cancer treatments.
A study has revealed an enzyme in bacteria that produces a molecule which is toxic to other bacteria and shows promise as an antibiotic substitute.
A new study has shown that restoring the amount of the kinase, HIPK2, in a kinase-depleted mouse model rescued it from heart failure and identifies HIPK2 as a novel regulator of heart failure progression.
A new study into the enzyme Cdc34 may make it possible to target the enzyme specifically to develop new cancer therapeutics.
A study has found a selective inhibitor for an enzyme that allows cancer cells to mutate and become resistant to treatments.
New research provides insights into how cancers can arise when DNA polymerase delta is not functioning properly.
A team has discovered that fungi use the Diels-Alder reaction to assemble new compounds that have potential pharmaceutical uses.
Researchers have discovered an enzyme that is pivotal in deciding whether cells survive or die in inflammatory diseases, so provides a drug target.
A compound that promotes the rebuilding of the protective sheath around nerve cells damaged in multiple sclerosis has been developed.
Scientists reveal the atomic structure and regulative mechanism of the metabolic enzyme transhydrogenase.
New findings suggest a possible new treatment strategy for severe dengue disease using the tryptase inhibitor, nafamostat mesylate.
A gene associated with a rare balance disorder also regulates the behaviour of an enzyme that increases the risk for Alzheimer's disease.
A pharmaceutical target has been identified by Duke University that, when activated, can reverse bone degradation caused by osteoporosis.
A new study has revealed that M. tuberculosis uses a unique type of antacid which gives immune cells indigestion, enabling the bacteria to survive.
Researchers have discovered that removing the enzyme, PHLPP1, improves outcomes in a mouse model of sepsis so could be a potential drug target.